Common themes in the pathogenesis of acute myeloid leukemia

Oncogene
M AlcalayP G Pelicci

Abstract

The pathogenesis of acute myeloid leukemia is associated with the appearance of oncogenic fusion proteins generated as a consequence of specific chromosome translocations. Of the two components of each fusion protein, one is generally a transcription factor, whereas the other partner is more variable in function, but often involved in the control of cell survival and apoptosis. As a consequence, AML-associated fusion proteins function as aberrant transcriptional regulators that interfere with the process of myeloid differentiation, determine a stage-specific arrest of maturation and enhance cell survival in a cell-type specific manner. The abnormal regulation of transcriptional networks occurs through common mechanisms that include recruitment of aberrant co-repressor complexes, alterations in chromatin remodeling, and disruption of specific subnuclear compartments. The identification and analysis of common and specific target genes regulated by AML fusion proteins will be of fundamental importance for the full understanding of acute myeloid leukemogenesis and for the implementation of disease-specific drug design.

References

Apr 15, 1976·Klinische Wochenschrift·D LangG von Bernuth
Apr 1, 1992·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·H TüchlerB Jaksic
Jun 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·M AlcalayP G Pelicci
Apr 1, 1992·Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society·P CuginiA Cianetti
Jan 1, 1992·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·L Degos
Sep 23, 1989·Lancet·C ChomienneL Degos
Feb 7, 1987·Lancet·H TominagaK Imamura
May 1, 1995·Developmental Dynamics : an Official Publication of the American Association of Anatomists·A SimeoneF Calabi
Apr 1, 1995·Molecular and Cellular Biology·S MeyersS W Hiebert
Dec 1, 1993·Current Opinion in Cell Biology·R Paro
Oct 1, 1994·Molecular and Cellular Biology·Z M MuK S Chang
Oct 25, 1994·Proceedings of the National Academy of Sciences of the United States of America·N J Zeleznik-LeJ D Rowley
Dec 6, 1994·Proceedings of the National Academy of Sciences of the United States of America·M J ThirmanJ D Rowley
Jun 21, 1994·Proceedings of the National Academy of Sciences of the United States of America·S A SchichmanC M Croce
Oct 1, 1993·Trends in Genetics : TIG·H KagoshimaP Gergen
Jul 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·E OgawaY Ito
May 21, 1993·Cell·D LohnesP Chambon
May 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·T NakamuraP C Nowell
Dec 15, 1995·Cell·D J Mangelsdorf, R M Evans
Apr 16, 1996·Proceedings of the National Academy of Sciences of the United States of America·Q WangN A Speck
Oct 29, 1996·Proceedings of the National Academy of Sciences of the United States of America·K SasakiT Komori
Sep 1, 1996·Acta Anaesthesiologica Scandinavica·B WåhlinL G Hellström
Oct 1, 1996·Current Opinion in Genetics & Development·S Minucci, K Ozato

❮ Previous
Next ❯

Citations

May 19, 2004·The International Journal of Biochemistry & Cell Biology·Hiroshi Kawamoto, Nagahiro Minato
Jun 21, 2005·The International Journal of Biochemistry & Cell Biology·Lucia AltucciHinrich Gronemeyer
Oct 14, 2003·Cancer Genetics and Cytogenetics·Sílvia CasasSakari Knuutila
Mar 29, 2003·Regulatory Toxicology and Pharmacology : RTP·Richard AlbertiniCurtis Travis
Nov 1, 2003·Best Practice & Research. Clinical Haematology·Elisabeth Paietta
Nov 1, 2003·Best Practice & Research. Clinical Haematology·Francesco Lo-CocoWilson H Miller
Feb 16, 2010·Expert Reviews in Molecular Medicine·Constanze Bonifer, David T Bowen
Nov 26, 2002·Seminars in Hematology·D Gary Gilliland
Sep 25, 2003·Proceedings of the National Academy of Sciences of the United States of America·Emmanuelle PasseguéIrving L Weissman
May 10, 2005·Genes & Development·Jill WildongerRichard S Mann
May 26, 2005·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Simona RonzoniSaverio Minucci
Oct 9, 2003·British Journal of Haematology·Masuzu UedaHiroyuki Mano
Mar 28, 2003·Genes, Chromosomes & Cancer·Alain CharestDavid Housman
May 12, 2006·Cancer·Raoul TibesStefan Faderl
Aug 19, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·John Ansell
Oct 21, 2005·Critical Reviews in Oncology/hematology·Björn SteffenHubert Serve
Dec 9, 2003·The Journal of Clinical Investigation·Myriam AlcalayPier Giuseppe Pelicci
May 29, 2002·Oncogene·Joseph M ScanduraStephen D Nimer
Mar 28, 2003·Oncogene·Bin ZhangRobert G Fenton
Aug 27, 2019·Journal of Cellular and Molecular Medicine·Haiyan XuHongmin Chen
May 10, 2005·Blood·Torsten HaferlachClaudia Schoch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.